Introduction
============

The consistent development of antibiotic resistance in life-threatening pathogens diminishes the availability of effective medications for the treatment of infectious diseases. Natural products originating from plants and microorganisms have inspired medicinal drug research for decades ([@B61]). They are produced as secondary metabolites and represent a major source of drug leads and serve as templates for semisynthetic derivatives. A vast number of secondary metabolites from microorganism, particularly from actinobacteria have been described to date. *Actinobacteria* represent one of the most thoroughly examined group of bacteria in terms of natural product research, which is reflected in the continuing discovery of important antibiotics, e.g., teicoplanin, daptomycin, and fidaxomicin over the years ([@B50]). Many natural products not only serve as antibiotics but also as antiviral, immunosuppressive and even as anticancer agents ([@B60]). Hence, the discovery of new bioactive natural products is still indispensable for sustaining the rapid progress of medicinal research ([@B13]).

A large proportion of biologically active secondary metabolites are polyketide derivatives. These compounds are assembled by polyketide synthases (PKSs), enzymes that conduct a simple repetitive condensation of acyl units to form poly-ß-ketide chains followed by conversion of the chain into structurally diverse metabolites. Depending on the structure and the enzymatic pathway, PKSs can be divided into three major types. Type I PKSs have modular architectures consisting of several modules each harboring ketosynthase (KS) and acyl carrier protein (ACP) domains accompanied by an acyltransferase domain (AT), which is responsible for the selection of the extender unit, as well as a set of processing enzymes (KR -- ketoreductase, DH -- dehydratase, and ER -- enolreductase) ([@B32]). Recently, a new type of modular PKS was discovered that lacked the acyltransferase domains within the modular proteins ([@B24]). The acyltransferase activity is a standalone protein that is typically encoded within the respective gene cluster. PKSs of this type are known as trans-AT and they are believed to be the most abundant type of secondary metabolite assembly lines.

Bacterial strains of the genus *Streptomyces* inhabit different ecological niches. They are found not only in soil but also in fresh water systems, marine habitats, isolated eco-systems, and in symbiosis with insects and plants ([@B23]). Lake Baikal is a unique eco-system, rich in endemic species of living organisms. We have recently isolated a variety of actinobacteria strains from Lake Baikal ([@B3]). Several of these strains were found to be active against Gram-positive and Gram-negative bacteria. The strain *Streptomyces* sp. IB2014/011-12 showed the most promising results when tested against *Bacillus subtilis*. This finding motivated us to analyze the strain in its entirety to identify the metabolites responsible for the observed activity.

Here, we report the activity-guided screening of metabolites produced by *Streptomyces* sp. IB2014/011-12 that resulted in the isolation of alpiniamide A **(1)**, which was previously described as a product of the endophytic *Streptomyces* sp. YIM66017 ([@B20]), and its novel derivatives. The genome of this strain has been sequenced and analyzed, which has enabled us to identify the gene cluster responsible for the biosynthesis of alpiniamides.

Materials and Methods {#s1}
=====================

Bacterial Strains, Culture Conditions, and General Procedures
-------------------------------------------------------------

The isolation and phylogenetic characterization of *Streptomyces* sp. IB2014/011-12 were reported in ([@B3]). *Streptomyces* strains were grown on solid nutrient medium MS (mannitol soy flour agar) and in liquid TSB medium ([@B33]). For secondary metabolite production, NL19 (MS medium without agar) and SG (glucose, yeast, Bacto Soytone, and calcium carbonate) medium have been used. *Escherichia coli* XL1Blue (Agilent, United States) was used for routine cloning, and *E. coli* MW 6026 was used as a donor in the intergenic conjugation ([@B7]). *E. coli* strains were grown in Luria-Bertani (LB) broth. For MW 6026, diaminopimelic acid was added. When required, antibiotics were added to the cultures at the following concentrations: 50 μg ml^−1^ apramycin, 100 μg ml^−1^ spectinomycin, 100 μg ml^−1^ phosphomycin, and 100 μg ml^−1^ carbenicillin (Sigma, United States; Roth, Germany).

Recombinant DNA Techniques
--------------------------

Chromosomal DNA from *Streptomyces* strains and plasmid DNA from *E. coli* were isolated using standard protocols ([@B41]; [@B33]). Restriction enzymes and molecular biology reagents were used according to the recommendations of the supplier (Thermo Fisher Scientific, Germany; NEB, **United States**).

Genome Sequencing, Assembly, and Annotation
-------------------------------------------

For DNA isolation, *Streptomyces* sp. IB2014/011-12 was inoculated into TSB medium and grown at 28°C with shaking (200 rpm) for 3 days. High quality total cellular DNA was isolated using salting out procedure. The purity and concentration of the genomic DNA was determined using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific).

For sequencing of the *Streptomyces* sp. IB2014/011-12 genome, an Illumina paired-end sequencing library (TruSeq sample preparation kit; Illumina, United States) was constructed according to the manufacturer's protocol. The *Streptomyces* sp. IB2014/011-12 draft genome sequence was established on an Illumina HiSeq system in rapid run mode (2 × 250 nt) with a pair distance of about 500 bp. Upon sequencing and processing of the obtained data, a *de novo* assembly was performed using the GS De Novo Assembler (version 2.8.) (Roche Diagnostics, Mannheim, Germany) with default settings. Annotation of the genome was performed by means of prokka v1.11 and the GenDB 2.0 platform ([@B45]; [@B55]). For the identification of secondary metabolites clusters antiSMASH 3.0 was used ([@B62]). The assembled and annotated draft sequence of the *Streptomyces* sp. IB2014/011-12 genome was deposited in the GenBank database under accession number [QEIK00000000](QEIK00000000).

Generation of the Construct for Gene Cluster Inactivation
---------------------------------------------------------

Two DNA fragments, C9-1 and C9-2, flanking the first 2000 bp of the gene *alpA1* have been amplified using the primer pairs C9-2REcV and C9-2FEcI and C9-1FEcV and C9-1RXba (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). The obtained 2 kb fragments were cloned into a pST Blue-I AccepTor^TM^ vector (Novagen, United States). The construct containing fragment C9-1 was digested with *Eco*RV (primer) and *Xba*I (vector MCS) and ligated with the C9-2 fragment, which was retrieved with the same restriction enzymes. The resulting plasmid was digested with *Eco*RV and ligated with the spectinomycin-resistance cassette. The final construct was transformed into pKG 1132 ([@B47]). This construct was transferred into *Streptomyces* sp. IB2014/011-12 via an intergeneric conjugation. The exconjugants were grown under non-selective conditions and screened for white spectinomycin-resistant colonies when grown on MS supplemented with X-gluc (X-Gluc DIRECT, United States). The deletion of part of the *alpA1* gene was confirmed by PCR using the 11-12DelCheckF and 11-12DelCheckR primer pair (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**).

Cloning of the *alp*-Gene Cluster and Red/ET Mediated Gene Deletion
-------------------------------------------------------------------

The two 2.5 kb DNA fragments, Tar1 and Tar2, flanking a 46.7 kb region of the *Streptomyces* sp. IB2014/011-12 chromosome that includes the entire *alp*-gene cluster were amplified with the primer pairs 11-12C9TarF1Not and 11-12C9TarR1Nhe and 11-12C9TarF2NheI and 11-12C9TarR2HindIII, respectively (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**), using Phusion DNA polymerase and cloned into the pJET1.2 vector (Thermo Fisher Scientific, **United States**). Fragments were assembled by digesting the Tar1-containing plasmid with *Nhe*I (primer) and *Hind*III (vector MCS) and ligating with the *Nhe*I/*Hind*III-retrieved Tar2 fragment. The resulting construct was sub-cloned into a *Nhe*I/*Hind*III-digested pCLY10 vector ([@B6]). The final construct was linearized with *Nhe*I and mixed with *Streptomyces* sp. IB2014/011-12 chromosomal DNA in a 1:5 ratio. The mixture was transformed into *S. cerevisiae* BY4742 ([@B64]) with the standard LiAc protocol ([@B19]). Transformants were selected on YNB medium supplemented with yeast synthetic drop-out medium supplements without leucine (Sigma-Aldrich, United States). Colonies were plated in patches of 100, washed, and analyzed by PCR for the presence of clones harboring the desired construct using the primers 11-12C9CheckHind (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**) annealed to the cloned region outside of the homology fragment and pCLYCheckHind (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**) annealed to the vector. The positive clone was further pooled out, the total DNA was purified using a standard protocol ([@B21]) and transformed into *E. coli* XL1Blue to give 011-12p1-49 clone carrying the desired region of the *Streptomyces* sp. IB2014/011-12 chromosome. 011-12p1-49 plasmid DNA was purified and sequenced by MinION (Oxford Nanopore, United Kingdom). 011-12p1-49 was introduced into *S. lividans* TK24 and *S. albus* Del14 (unpublished data, Dr. M. Myronovskyi, personal communication) by intergeneric conjugation. The resulting strains were grown, and the production of alpiniamides was analyzed as described below. *alpD*, *alpR*, and *alpE* genes were inactivated by replacement with a hygromycin resistance cassette from plasmids patt-shyg ([@B47]) within the 011-12p1-49 construct. λ-Red recombineering was performed as described ([@B22]). Primers used to amplify the cassette and to verify the deletions are listed in **Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**. The resulting constructs were introduced into the host *S. albus* Del 14 via conjugation and clones were selected with hygromycin. The mutants were cultivated in NL19 and production was analyzed using LC-MS as described below.

Production, Extraction and LC-MS Analysis of Alpiniamides
---------------------------------------------------------

The *Streptomyces* sp. IB2014/011-12 was grown in 10 ml of TSB for 2 days at 28°C on a rotary shaker. The main culture (100 ml of NL19 in 500 mL flasks with glass beads) was inoculated with 1 ml of the pre-culture and cultivated at 28°C and 180 rpm for 7 days. The metabolites in the cultural liquid were extracted with ethyl acetate and from the biomass with a mixture of acetone and methanol (1:1). The solvents were evaporated, and the residue was dissolved in 300 μl of methanol.

The LC-MS data were collected on a Dionex Ultimate 3000 RSLC system using a BEH C18, 100 × 2.1 mm, 1.7 μm d~p~ column (Waters, Germany). Separation of a 1 μl sample was achieved by a linear gradient of solvent B (acetonitrile with 0.1% of formic acid) against solvent A (water with 0.1% of formic acid) at a flow rate of 600 μl/min and 45°C. The gradient started with a 0.5 min isocratic step of 5% B then increased to 95% B over 18 min and ended with a 2 min step of 95% B before re-equilibration under the initial conditions. UV spectra were acquired by a DAD in the range of 200 to 600 nm. The mass spectrometry data were collected on an amazon SL speed mass spectrometer (Bruker Daltonics, Germany) using an Apollo II ESI source. Mass spectra were acquired in centroid mode ranging from 200 to 2000 *m/z* at a scan rate of 2 Hz. The HRMS data were collected on a Dionex Ultimate 3000 RSLC system using a BEH C18, 100 × 2.1 mm, 1.7 μm d~p~ column (Waters, Germany). Separation of a 1 μl sample was achieved by a linear gradient of solvent B (acetonitrile with 0.1% of formic acid) against solvent A (water with 0.1% of formic acid) at a flow rate of 480 μl/min and 45°C. The gradient started with a 0.5 min isocratic step of 5% B then increased to 95% B over 20 min and ended with a 2 min step of 95% B before re-equilibration under the initial conditions. UV spectra were acquired by a DAD in the range of 200 to 600 nm. High-resolution mass spectrometric data were collected on an LTQ Orbitrap mass spectrometer (Thermo Fischer Scientific, United States).

Data were collected and analyzed with the Bruker Compass Data Analysis software, version 4.2 (Bruker, Billerica, MA, United States) and the Thermo Xcalibur software, version 3.0. The screening for known compounds was performed using the Dictionary of Natural Products Database, version 10.0 (CRC Press, Boca Raton, FL, United States), using the following parameters: accurate molecular mass, absorption spectra and biological source ([@B51]). Compounds were considered to be similar when the difference in accurate mass was less than 2 ppm and the absorption spectra were identical.

Feeding Experiments
-------------------

Thirty milliliter of liquid NL19 medium was inoculated with 300 μl of a 22 h old seed culture of the strain *Streptomyces* sp. IB2014/011-12. After 10 h of growth on a rotary shaker at 28°C, the culture was supplemented with 200 μl of Glycine-2-^13^C or 200 μl methionine(-methyl-^13^C) respectively, solved in water (5.2 mg/ml). This procedure was repeated four times every 10--12 h. The final concentration of compounds in the flask was 2.31 mM of Glycine-2-^13^C and 1.16 mM of methionine(-methyl-^13^C). After 7 days of cultivation, the culture was extracted separately, biomass with acetone/methanol (1:1) and the supernatant with ethyl acetate. The solvent was evaporated and the obtained residues solved in MeOH. The extracts were subjected to LC-MS analysis.

Isolation and Structure Elucidation of Alpiniamides
---------------------------------------------------

For the isolation of the metabolites, the strain was cultivated as described above in 8 L of NL19. Metabolites were extracted from cultural liquid with equal volume of ethyl acetate, solvent was evaporated and resulting 1.56 g of crude extract was dissolved in 8.5 ml of methanol. The crude extract was purified through size-exclusion chromatography using Sephadex^®^ LH 20 (Sigma-Aldrich) and MeOH as eluent (1 m long column with 700 ml volume of Sephadex). Fractions were collected every 15 min with a speed of 1-2 drops per second (approximately 30 ml per hour). The obtained fractions with antibacterial activity were further purified by preparative and subsequent semipreparative high-performance-liquid-chromatography (HPLC) using the following equipment: Dionex Ultimate 3000 from ThermoScientific (preparative) and Agilent 1260 Series and 1100 Series from Agilent Technologies (semipreparative). For preparative HPLC, a Nucleodur C18 HTEC column (150 × 21 mm, 5 μm) was used with a multistep gradient from 15--20% B (B: acetonitrile with 0.1% formic acid; A: water with 0.1% formic acid) over 2 min and 20--60% B over 20 min at a flow rate of 20 ml/min and 45°C. Semipreparative HPLC was performed using a Synergi Phusion RP-Column (250 × 10 mm, 4.6 μm; Phenomenex) with a gradient elution from 5 to 95% B (B: methanol with 0.1% of formic acid; A: water with 0.1% formic acid) over 20 min at a flow rate of 4.5 ml/min and 45°C. UV spectra were recorded with a DAD detector at 200--600 nm.

NMR spectra were acquired in deuterated methanol (CD~3~OD) and deuterated chloroform (CDCl~3~) at 298 K on a Bruker Avance III 700 or 500 MHz spectrometer, both equipped with a 5 mm TXI cryoprobe. NMR shifts were relative to the residual solvent signal CH~3~OD at δ 3.30 and CDCl~3~ δ 7.24 for ^1^H, or to the solvent itself at δ 49.00 (CD~3~OD) and 77.00 (CDCl~3~) for ^13^C measurements. NMR data were analyzed using Topspin, version 3.5 pl7 (Bruker, United States).

Preparation of the S- and R-MTPA-Ester of Alpiniamide A (6S and 6R), Alpiniamide B~1~ (7S and 7R), and Alpiniamide B~2~ (8S and 8R) by the Modified Mosher's Method
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a solution of alpiniamide A (**1**, 0.5 mg, 1.45 μmol) and dry pyridine (20 μl) in dry deuterated chloroform (100 μl) at room temperature, α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (R-MTPA-Cl) (20 μl, 0.10 mmol) was added. The reaction was mixed at room temperature for 4 h. Another 200 μl of CDCl~3~ was added, and the sample now containing the S-MTPA-ester of alpiniamide A (**6S**) was directly subjected to NMR measurements (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). The R-MTPA-ester of alpiniamide A (**6R**) was prepared in the same way using S-MTPA-Cl instead of its R-isomer. The same procedure was carried out with only a fifth of all ingredients to get **7S** and **7R** from alpiniamide B~1~ **(2)** and **8S** and **8R** from alpiniamide B~2~ **(3)**, respectively (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**).

Bioactivity Assay
-----------------

The antimicrobial activities of isolated compounds were measured by a disk diffusion assay. A 30 μl aliquot of each compound was loaded on a paper disk with a diameter of 6 mm, allowed to dry, and set on an LB agar plate coated with *B. subtilis* from liquid overnight culture. The plates were incubated at 37°C for 12 h. The zones of inhibition were measured manually. The minimal inhibitory concentrations were estimated by standard serial dilutions protocol in 200 μL in 96 well plates. Briefly, serial dilutions (1:1) of alpiniamides were prepared using DMSO as a solvent prior to aliquoting 10 μL of each solution into 96 well plate. Kanamycin was used as a positive control (full inhibition of growth), and DMSO was used for the negative control (full growth). 190 μL of bacterial test cultures in appropriate media (1:500 dilution of overnight culture) were added to each well, and the plates were shaken at 30°C for 16-20 h. Then, 5 μL of thiazolyl blue tetrazolium bromide (10 mg mL^−1^) solution was added to each well, and the plates were incubated at 30°C for an additional hour. MICs were determined as the concentration of antibiotic in the well where the additive did not change the color of the solution from yellow to dark blue.

Results
=======

Genome Analysis
---------------

S*treptomyces* sp. IB2014/011-12 has been isolated from the net-spinning caddisfly *Trichoptera* sp. (larvae) ([@B3]). Phylogenetic analysis based on the 16 sRNA showed that the strain IB2014/011-12 belongs to the genus *Streptomyces*. The strain grows as a typical actinobacteria forming colonies with aerial mycelia and gray spores (**Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}**). The strain accumulates a brownish pigment during growth on a solid medium. When grown in liquid media (NL19) the strain demonstrated activity against Gram-positive bacteria. The genome of *Streptomyces* sp. IB2014/011-12 has been sequenced and assembled into 71 contigs (**Table [1](#T1){ref-type="table"}**). The largest contig is 956.9 kbp. The overall size amounts to 8099.23 kbp, which is in the normal range for streptomyces. The genome consists of a single chromosome and has no extra chromosomal DNA based on the sequence coverage. The genome has a G + C content of 71.5%. The chromosome is predicted to contain 7.282 coding sequences, 5 rRNA clusters, 80 tRNA genes and one tmRNA gene ([@B48]). The analysis of the genome using antiSMASH software revealed that 29 gene clusters are involved in the biosynthesis of diverse secondary metabolites including terpenes, lanthipeptides, non-ribosomal peptides, and polyketides (**Supplementary Table [S2](#SM1){ref-type="supplementary-material"}**).

###### 

Features of *Streptomyces* sp. IB2014/011-12 genome.

  ------------- ------------
  Genome size   8099.23 bp
  Contigs       71
  GC content    71.5%
  CDS           7.282
  tRNA          80
  mRNA          1
  rRNA          5
  Cluster       29
  ------------- ------------

Based on the gene cluster analysis with antiSMASH the production of several secondary metabolites by *Streptomyces* sp. IB2014/011-12 can be predicted (**Supplementary Table [S2](#SM1){ref-type="supplementary-material"}**). Like most of actinobacteria strains, the genome contains gene clusters for desferrioxamine, ectoine, and melanin production. Desferrioxamine B, a high-affinity iron chelator (siderophore), is important for scavenging ferric iron as a nutrient for the cells ([@B4]). Ectoine, another common metabolite, is an osmoprotectant ([@B70]). The function of melanin, a black pigment, that is produced by many types of bacteria, is still under discussion ([@B65]). The compound is most likely involved in protection against chemical and biological stresses, such as exposure to heavy metals, oxidizing agents and UV radiation ([@B1]), and it might be the reason why the MS medium is colored by that strain (**Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}**). In addition, the gene cluster that produces the class III lantipeptide AmfS is present in the genome of *Streptomyces* sp. IB2014/011-12. The predicted amino acid sequence of the precursor peptide from the gene cluster coincides with the sequence of AmfS isolated from *Streptomyces griseus* ([@B59]). AmfS-like compounds are known to be positive regulators of the formation of aerial-mycelium in streptomyces. Another secondary metabolite that could be predicted from the *Streptomyces* sp. IB2014/011-12 genome analysis is roseoflavin. This compound belongs to the riboflavin antibiotic family, which targets riboswitches that affect bacterial growth ([@B42]; [@B52]). Furthermore, the gene cluster no. 3 is probably coding for the class II lasso peptide SRO15-2005 since it shows 100% sequence homology to the corresponding gene cluster of *S. roseosporus* NRRL 15998 ([@B31]).

Dereplication of Secondary Metabolites Produced by *Streptomyces* sp. IB2014/011-12
-----------------------------------------------------------------------------------

Dereplication is a quick and simple method of analyzing metabolites based on LC-MS data. It allows known compounds to be distinguished from potentially new metabolites to avoid their purification and analysis. With the help of UV/Vis spectra, high-resolution mass spectrometric data, biological source and other criteria, one can compare entries in data banks such as the "Dictionary of Natural Products (DNP)" in order to identify metabolites in the extract of interest ([@B63]). At first, to estimate the potential novelty of the compounds produced by *Streptomyces* sp. IB2014/011-12, we analyzed the LC-MS data of the extracts of the strain grown in NL 19 media. The obtained exact masses from MS data were further compared to the DNP. This led to the identification of some known compounds and prediction of putative new metabolites produced by this strain (**Figure [1](#F1){ref-type="fig"}**). The major class of compounds produced by this strain is polycyclic tetramate macrolactams (PTM) (**Supplementary Figures [S3](#SM1){ref-type="supplementary-material"}**, **[S4](#SM1){ref-type="supplementary-material"}**) ([@B67]). We identified alteramide A **(9)** ([@B56]) and several isomers that were not distinguishable since they all have *m/z* 511.28207 \[*M*+H\]^+^ (510.27427 \[*M*\], calculated 510.2730) ions and UV curves typical for PTMs but different retention times. Under the used conditions, the isomers elute at RTs of 17.7, 18.6 and 19.0 min. Alteramide B **(10)** and several isomers with *m/z* 495.28549 \[*M*+H\]^+^ (494.27769 \[*M*\], calculated 494.2781) were present in the extract as well. They eluted at RT 18.3, 18.9, 19.3, and 19.5 min. In addition to these, the strain also produces clifednamide A **(11)** (*m/z* 509.26395 \[*M*+H\]^+^, 508.25615 \[*M*\] calculated 508.2573, RT at 18.4) and clifednamide B **(12)** (*m/z* = 493.27017 \[*M*+H\]^+^, 492.26237 \[*M*\] calculated 492.2624, RT at 18.7) ([@B11]) and possible isomers of these compounds that eluted at different retention times (RT at 18.8 and 18.9 min). Furthermore, the compound eluting at RT 18.2 min with *m/z* 513.29565 \[*M*+H\]^+^ (512.28785 \[*M*\], calculated 512.2886) corresponds to dihydromaltophylin **(13)** (heat-stable antifungal factor, HSAF) ([@B38]).

![LC-MS chromatogram (minute 4 to 20 from an overall 20 min run) of extract of *Streptomyces* sp. IB2014/011-12 cultivated in NL19 medium. The peaks for different alpiniamides are marked with letters. Peaks for polycyclic tetramate macrolactams are highlighted with the bracket.](fmicb-09-01959-g001){#F1}

Alteramide A and B, isolated from marine bacterium *Alteromonas species*, are macrocyclic lactams that contain a dienone and a dienoyl tetramic acid moiety ([@B56]; [@B14]). They exhibit activity against leukemia cells but are not active against bacteria. Dihydromaltophilin is similar to alteramide in that it also has three five-membered rings. The compound was isolated from *S. maltophilia* R3089 and exhibits activity against a broad spectrum of fungi but is not active against Gram-positive or Gram-negative bacteria ([@B28]). The clifednamides, another group of PTMs, were first isolated from *Streptomyces* sp. JV178. The biological activity of these compounds has not yet been published. In the genome of *Streptomyces* sp. IB2014/011-12, a hybrid type I PKS-NRPS cluster no. 13 has been identified, and it is similar to the known gene clusters for PTMs biosynthesis (**Supplementary Figure [S5](#SM1){ref-type="supplementary-material"}**). The biosynthetic gene cluster for alteramide, clifednamide and dihydromaltophilin differ slightly in their structures. Cluster no. 13, with the core gene coding for iterative hybrid NRPS-type I PKS, provide all necessary enzymatic activities for PTM production (CDCs: 14650--14675, **Supplementary Figure [S5](#SM1){ref-type="supplementary-material"}**). The gene cluster encodes for a putative hydroxylase (14675), an iterative type 1 PKS-NRPS (14670), two oxidoreductases (14665--14660), alcohol dehydrogenase (14655), and cytochrome P450 hydroxylase (14650) in the same arrangement as in the biosynthetic gene cluster for HSAF and frontalamides ([@B40]).

Isolation and Structure Elucidation of Alpiniamide A--D (1--5)
--------------------------------------------------------------

*Streptomyces* sp. IB2014/011-12 produced additional metabolites (**Figure [1](#F1){ref-type="fig"}**) that we could not dereplicate against known products. For this reason, we assumed that the activity was caused by potentially new metabolite(s). We grew the strain in 8 L of NL19 and extracted the produced metabolites. Subsequently, a bioactivity-guided purification was carried out by tracking down the bioactive compounds using the disk diffusion assay at each step of purification. The crude extract was first fractionated using size-exclusion chromatography, and the obtained fractions were tested against *B. subtilis*. The active fractions were combined and further purified with preparative HPLC and then with semipreparative HPLC. The fractions collected after each separation step were tested for antibacterial activity. This resulted in the isolation of five compounds. The structure elucidation showed that they are alpiniamides (**Figure [2](#F2){ref-type="fig"}**).

![Revised structure of alpiniamide A **(1)** and structures of new alpiniamides B-D **(2--5)** from *Streptomyces* sp. IB2014/11-12.](fmicb-09-01959-g002){#F2}

**Alpiniamide A (1)** was obtained as a slightly red solid (4 mg), with a molecular formula of C~17~H~29~NO~6~ as determined by high-resolution electrospray ionization mass spectrometry (HRESIMS) at *m/z* 344.20596 \[*M*+H\]^+^, indicating 4 degrees of unsaturation. Its NMR spectra, acquired in CD~3~OD (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}**) revealed 17 carbons, five methyls (one adjacent to a double bond), two methylenes, six methines (two secondary alcohols and one as part of a double bond), and four quarternary carbons (three carbonyls and one as part of a trisubstituted double bond). The chemical shifts of the methylene group at δ~H~ 4.13 and 4.25 and δ~C~ 49.0 indicated the presence of an amide nitrogen atom nearby. These data together with the results of 2D ^1^H-^1^H-COSY, HSQCED, HMBC, and ROESY led to the structure of alpiniamide, which was previously isolated from the *Streptomyces* sp. YIM660107 ([@B69]), with NMR data recorded in CDCl~3~. In order to compare the literature data with our data, we reran the 1D NMR spectra of **1** in CDCl~3~ (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}** and **Supplementary Figures [S6](#SM1){ref-type="supplementary-material"}**, **[S7](#SM1){ref-type="supplementary-material"}**). The obtained data were close to those from the reported structure. But the remarks to the relative stereochemistry of alpiniamide were confusing. C-2/C-3 was found to be *threo*, but the structure of alpiniamide showed the *erythro*-form. C-2′/C-3′/C-4′ was announced as *threo* as well, which is ambiguous and most likely a wrong phrasing for a system with three chiral centers. However, the structure showed C-2′/C-3′ and C-3′/C-4′ both in *erythro*-configuration. Therefore, we were motivated to investigate the stereochemistry of **1** in more detail.

Due to the large vicinal coupling constant of 9.5 Hz for *J*~H2H3~, the configuration for C-2/C-3 in part A (C-1 to C-9) was found to be *threo*. We are aware, that a single coupling constant cannot usually distinguish which of two diastereomers might be present since there are three possible staggered conformations for each diastereomer, two of which will typically have very similar predicted coupling constants for a pair of vicinal protons. But assignments become possible when one can make some reliable predictions on which conformation predominates. Such a situation is given for part A of **1**, where the hydroxyl at C-3 can form an intramolecular hydrogen bond with carbonyl C-1 when measured in the non-polar solvent CDCl~3~. Then, the ^3^*J*~HH~ coupling constant of two vicinal protons are considerably large when they are in the *threo* configuration. Small values for ^3^*J*~HH~ indicate the *erythro* form ([@B57]; [@B25]). A similar situation predominates in part B between the hydroxyl at C-3′ and the carbonyls C-1′ and C-5′. Careful analysis of ^3^*J*~HH~ coupling constants led to 7.0 Hz for *J*~H2′H3′~ and 4.5 Hz for *J*~H3′H4′~. The small coupling constant for H-3′/H-4′ give rise to an *erythro* configuration, whereas the moderate high *J* value for H-2′/H-3′ is a hint for the *threo*-form (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}**) ([@B66]). Nevertheless, a final proof of the relative stereochemistry of **1** requires a complete set of ^3^*J*~HH~ and ^2,3^*J*~HC~ coupling constants as shown in Murata's method ([@B44]; [@B5]). Due to the limited amount of **1** and its insufficient stability during storing, we were not able to perform it.

In order to determine the absolute configuration as well, we applied Mosher's method ([@B12]; [@B26]). Portions of **1** were separately treated with (R)-MTPA-Cl and (S)-MTPA-Cl to yield the Mosher ester **6S** and **6R**, respectively (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**). The differences in the proton chemical shifts of **6S** and **6R** (Δδ~(S-R)~) should give positive or negative values from which the configuration can be established. For part A of the molecule we obtained negative values for H-2 and H-8 and positive values for H-5, H-6, H-7, and H-9 (**Supplementary Table [S4](#SM1){ref-type="supplementary-material"}** and **Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}**). On the basis of these results, the absolute configuration can be determined as *R* at C-3. From the relative configuration, the neighboring positions can also be assigned, resulting in *R*-configuration at C-2. The results for part B are less clear. We obtained negative values for H-2,' and positive values for H-4,' H-7,' and H-8'. For an appropriate interpretation H-2' and H-7' should have one sign and H-4' and H-8' the opposite sign. However, H-7' does not coincide with this rule and makes therefore a distinct statement about the absolute configuration for H-3′ impossible. Such issues with the assignment of the absolute configuration with MTPA are known for linear secondary alcohols ([@B54]). The reason for inconsistent sign distribution and small Δδ~(S-R)~ values often lies in the presence of different conformers of the MTPA ester. Theoretical calculations revealed that a rotation about the C~α~ -- CO and C~α~ -- Ph bond generates three conformers ([@B37]). All three conformers are present in similar populations and each conformer has a different shielding/deshielding effect, and therefore it influences the final spectrum in different ways. This information together with the inconsistent results from Mosher's method for the identical parts of the close related compounds **2** and **3** (see below) hinders the assignment of the absolute configuration for C-3′. Alternative reagents, e.g., methoxyphenylacetic acid (MPA) or α-(9-anthryl)-α-methoxy-acetic acid (9-AMA) should give more precise values ([@B54]). Due to the little amount of **1** we had to refrain from further efforts to determine the absolute configuration for this part of the molecule.

Therefore, the structure of **1** was established as shown in **Figure [3](#F3){ref-type="fig"}**. We named it alpiniamide A, due to the close relationship to alpiniamide from a *Streptomyces* species mentioned above. It is not excluded that alpiniamide and alpiniamide A have identical structures. But due to the confusion concerning the relative configuration of alpiniamide in the literature and the lack of coupling constants especially for H-2′-H-4′, we were not able to determine it.

![Mass spectra of alpiniamide A (*m/z* 326.32 \[*M*-H~2~O+H\]^+^) extracted from *Streptomyces* sp. IB2014/011-12 culture cultivated in the presence of unlabelled **(A)** and ^13^C labeled **(B)** glycine and unlabelled **(C)** and ^13^C labeled **(D)** methionine. The % of isotope containing ions is indicated.](fmicb-09-01959-g003){#F3}

**Alpiniamide B~1~ and B~2~ (2 and 3)**, were both isolated as red solids (0.5 mg), with a molecular formula of C~17~H~29~NO~6~ as determined by their HRESIMS data (*m/z* 344.20596 \[*M*+H\]^+^). The ^1^H NMR data (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}** and **Supplementary Figures [S9](#SM1){ref-type="supplementary-material"}**, **[S10](#SM1){ref-type="supplementary-material"}**) of both epimers were very close to each other and to those found for **1**. But in contrast to it, the double bond in part A of **2** and **3** was shifted from C-4 to C-3 and the secondary alcohol from C-3 to C-5. The only difference between alpiniamide B~1~ and B~2~ was found in the stereochemistry of the secondary alcohol at C-5. When applying Mosher's method to both isomers, the stereocenter at C-5 was assigned as *S* in alpiniamide B~1~ and *R* in alpiniamide B~2~ (**Figure [2](#F2){ref-type="fig"}**, **Supplementary Table [S4](#SM1){ref-type="supplementary-material"}**, and **Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}**). Due to the high conformity in the chemical shifts of H-2 and its neighboring atoms the configuration at C-2 is the same in both molecules and most likely *R* as it is given for alpiniamide A. The *E*-geometry of the double bond C-3/C-4 was confirmed by ROESY measurements with key correlation between double bond proton H-3 and the H-5 of the secondary alcohol. Part A is identical in all three alpiniamides. Even the coupling constants for H-2′, H-3,′ and H-4′ of the three compounds were identical indicating the same stereochemistry for this substructure in all three molecules. As for alpiniamide A, the determination of the absolute stereochemistry via Mosher's method failed for **2** and **3** due to the anomaly of the detected Δδ(~S-R~) values (**Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}**).

**Alpiniamide C (4)** was obtained as a white solid (0.8 mg) with a molecular formula of C~17~H~27~NO~5~ as determined from its HRESIMS at *m/z* 326.19589 \[*M*+H\]^+^. The mass difference of 18 units compared to **1--3** indicated the loss of a water molecule. The ^1^H and ^13^C resonances (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}** and **Supplementary Figure [S11](#SM1){ref-type="supplementary-material"}**) lacked one methine and a secondary alcohol function. Instead, resonances for an additional trisubstituted double bond (δ~H~ 6.87; δ~C~ 134.8 and 147.0) appeared in the spectra. The chemical shifts of part A were close to those of **1**. Therefore, the additional double bond must be located in part B. Its position between C-3′ and C-4′ was established by HHCOSY correlations starting from methyl H-7′ (δ~H~ 1.29 d, 7.0 Hz) via H-2′ (δ~H~ 3.40 m) to H-3′ (δ~H~ 6.87 d, 9.5 Hz).

**Alpiniamide D (5)** is the derivative with the lowest molecular mass. It is a colorless solid (0.4 mg) with a molecular formula of C~14~H~23~NO~5~ as determined from its HRESIMS at *m/z* 286.16458 \[*M*+H\]^+^. Due to its NMR data, part B of **5** is identical to that of **1**. However, signals for methines C-2 and C-3 and methyl C-8 in part A were missing in the spectra of **5** (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}** and **Supplementary Figure [S12](#SM1){ref-type="supplementary-material"}**) and gave therefore a hint of their deletion in part A. Vicinal HMBC correlations from carbonyl C-1 (172.2) to the double bond proton at δ~H~ 6.39 and the adjacent methyl protons at δ~H~ 1.84 supported this observation and led to structure **5** for alpiniamide D.

Alpiniamide A was previously isolated from the *Streptomyces* sp. YIM 66017. The crude extract of that strain was tested against the *Bacillus anthracis* and fungi *Fusarium solani* ([@B69]). In both cases inhibition zones were observed. Hence, we have tested the known alpiniamide A and its derivatives C and D on a panel of bacterial and yeast test cultures. The minimal inhibitory concentration (MIC) was determined against the Gram positive bacteria *Staphylococcus carnosus* DSMZ 20501, *Kocuria rhizophila* DSMZ 348, *Enterococcus mundtii* DSMZ 4840, *Micrococcus luteus* DSMZ 1790, *Mycobacterium smegmatis* DSMZ 43286, and *B. subtilis* DSMZ 10, against the Gram negative bacteria *Erwinia persicina* DSMZ 19328 and *Pseudomonas putida* KT2440 and against yeast *Candida glabrata* DSMZ 11226. In all cases we did not observe growth inhibitory activity in the concentration range up to 100 μg/ml. Also, pure compounds were found to be not active against *B. subtilis* in disk diffusion test. Since the mixture of all alpiniamides in the last stage of the purification was clearly active against *B. subtilis* we assume that the inhibitory concentration of alpiniamides lies above 100 μg/ml or the observed antibacterial activity is caused by synergistic effect with some minor compound(s).

Feeding Experiments
-------------------

From the structures of the isolated compounds we can predict that they are synthesized by the combined action of NRPS and PKS enzymes. The left and the right sides of the amide bond are typical products for a type I PK, whereas the peptide bond in the middle most likely arises from the amino acid glycine introduced by an NRPS enzyme. The methyl groups of the alpiniamides could originate from the direct use of methylmalonate during polyketide assembly or from a secondary methylation event with S-adenosyl methionine (SAM) as a donor. We grew two cultures of *Streptomyces* sp. IB2014/011-12 fed with ^13^C-labeled glycine and with ^13^C-labeled methionine (methyl-^13^C), respectively. The glycine was fed for the first time at 10 h post-inoculation. Methionine was fed for the first time at 36 h after inoculation. For both compounds, the feeding was repeated four more times every 10 h resulting in final concentration 2.31 mM of Glycine-2-^13^C and 1.16 mM of methionine(-methyl-^13^C). As a control, the culture supplemented with the corresponding unlabeled compound was used. The metabolites were extracted and analyzed by LC-MS. As result, the +1 isotopic peaks of all alpiniamides in the ^13^C-labeled glycine culture increased in intensity (42%) indicating the successful incorporation of the compound (**Figures [3A,B](#F3){ref-type="fig"}**). In contrast, the +1 isotopic peaks of alpiniamides in the culture supplemented with unlabeled glycine were observed at their normal intensity (19%). In the case of methionine, the results demonstrated the successful incorporation as well. The +1 isotopic peak of alpiniamides in the ^13^C-labeled methionine culture reached an intensity of 38.7% (**Figures [3C,D](#F3){ref-type="fig"}**). The +1 isotopic peaks of alpiniamide in the unlabeled culture appeared at their normal intensity of 20%. These results suggest that glycine is incorporated intact into alpiniamides and is the source of the amino group. On the other hand, we confirmed that at least some methyl groups originate from the SAM-dependent C-methyltransferase activity rather than methylmalonate.

Alpiniamide Gene Cluster Inactivation and Heterologous Expression
-----------------------------------------------------------------

The labeled substrate feeding tests suggest that the alpiniamides probably arise from the action of a hybrid PKS/NRPS assembly line that facilitates the incorporation of glycine. The only gene cluster in the genome of *Streptomyces* sp. IB2014/011-12 that corresponds to the hypothesized biosynthetic scheme is no. 9 (**Figure [6A](#F6){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**). This cluster encodes a hybrid NRPS-trans-AT-PKS that consists of four ketosynthase and one NRPS modules and a single NRPS module with an adenylation domain predicted to be specific for glycine as substrate. Two PK modules contain SAM-dependent C-methyltansferase domains. Overall, the architecture of the PKS-NRPS enzymes of cluster no. 9 suggests that it might be involved in the biosynthesis of alpiniamides. To verify this assumption, we replaced 2 kb of gene 12750 encoding the first PKS megaenzyme and its promoter with the spectinomycin-resistance cassette. The deletion was achieved through targeted gene disruption via double homologous recombination. The utilization of the pKG1132 suicide vector simplified the selection of colonies with double crossover by blue-white phenotypes due to the presence of the *gusA* gene in the vector backbone ([@B47]). The mutant strain and the wild type were cultivated in NL19 production medium, and the produced metabolites were analyzed by LC-MS. Compared to the wild-type strain, the mutant IB2014/011-12ΔalpA1 completely lacks the ability to produce alpiniamides (**Figure [4](#F4){ref-type="fig"}**). This proves that gene cluster no. 9, designated *alp*-cluster (**Table [2](#T2){ref-type="table"}**), is indeed responsible for the biosynthesis of alpiniamides.

###### 

Description of alpiniamide biosynthesis gene cluster and deduced function of *alp*-genes.

  ID      Name      Predicted function                                        Closest characterized homologs (% of identical amino acids)                                          GenBank accession number
  ------- --------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------- --------------------------
  12715   *alpI*    fatty acyl-CoA reductase                                  putative short chain dehydrogenase, hitachimycin, 46% (*Streptomyces scabrisporus*)                  LC008143
  12720   *alpH*    TetR family transcriptional regulator                     ^∗^TetR/AcrR family; *Streptomyces* sp. IB2014 011-1 (100%)                                          \-
  12725   *alpW*    transporter, ATP binding protein                          UvrA-like protein, quinomycin, 76% (*Streptomyces griseovariabilis*)                                 JN852959
  12730   *alpG*    glyoxalase protein                                        putative lyase, pentalenolactone, 82% (*Streptomyces avermitilis*)                                   BA000030
  12735   *alpF*    transcriptional activator/DNA repair enzyme               putative AraC-family transcriptional regulator, pentalenolactone, 86% (*Streptomyces avermitilis*)   BA000030
  12740   *alpT*    malonyl-CoA ACP transacylase                              acyltransferase/oxidoreductase, chivosazole, 50% (*Sorangium cellulosum*)                            DQ065771
  12745   *alpE*    3-oxoacyl-ACP synthase 3                                  3-oxoacyl-ACP synthase, cosmomycin D, 48% (*Streptomyces olindensis*)                                JJOHO1000002
  12750   *alpA3*   PKS: KS, AT, ACP; KS, DH, KR, ACP                         polyketide synthase, kijamimicin 48% (*Actinomadura kijaniata*)                                      EU301739
  12755   *alpA2*   PKS: KS, ACP, cMT, TE                                     polyketide synthase, bacillaene, 38% (Bacillus amyloliquefaciens)                                    AJ634060
  12760   *alpA1*   PKS/NRPS: C, A, PCP; KS, ACP, cMT; KS, DH, tDH, KR, ACP   OnnI, Onnamide, 44% (*Candidatus Entotheonella* sp.*)*                                               AY688304
  12765   *alpD*    acyl-CoA dehydrogenase                                    ^∗^acyl-CoA dehydrogenase, dutomycin, 88% (*Streptomyces minoensis*)                                 KP710956
  12770   *alpR*    ribosomal RNA large subunit methyltransferase G           methyltransferase containing protein; *Streptomyces* sp. IB2014 011-1 (100%)                         \-

∗

shown are closest homologs.

![Production of alpiniamides A-B (*m/z* 326 \[*M*-H~2~O+H\]^+^) and alpiniamide C (*m/z* 308 \[*M*-H~2~O+H\]^+^) by *Streptomyces* sp. IB2014/011-12 and its mutant strain IB2014/011-12ΔalpA1 lacking *alpA1* gene. LC-MS chromatogram RT 2--6 min out of an overall 9 min gradient run is shown. Black line -- extract of wild type *Streptomyces* sp. IB2014/011-12 and red line -- extract of mutant strain lacking part of *alpA1* gene and its promoter. Strains were cultivated for 7 days in NL19 medium. The peaks for alpiniamides are highlighted. Alpiniamide D elutes under these conditions together with main alpiniamides A and B.](fmicb-09-01959-g004){#F4}

In addition, we have cloned the 46.7 kb region of the chromosome of *Streptomyces* sp. IB2014/011-12 harboring the entire *alp* gene cluster and surrounding regions using transformation associated recombination in yeast. The cloning of the right region of *Streptomyces* sp. IB2014/011-12 chromosome and overall architecture of the cluster was verified through sequencing with MinION (Oxford Nanopore, United Kingdom). The construct was introduced into *S. lividans* TK24 and *S. albus* Del14. The recombinant strains bearing the cloned *alp*-gene cluster were found to produce alpiniamides (**Figure [5](#F5){ref-type="fig"}**). However, we were able to identify only alpiniamides A, B, and C in the extracts of generated strains. The lack of alpiniamide D could be caused either by a change in the behavior of the enzymatic assembly line or by the relatively low production of this minor derivative, hindering its identification. Moreover, a set of mutant constructs with deletion of *alpD*, *alpR*, and *alpE* genes were created. The resulting plasmids were introduced into *S. albus* Del14 and analyzed for production of alpiniamides. The deletion of *alpD* encoding an acyl-CoA dehydrogenase and *alpR* encoding a ribosomal RNA methyltransferase (**Table [2](#T2){ref-type="table"}**) had no significant effect on the production of compounds (**Supplementary Figure [S13](#SM1){ref-type="supplementary-material"}**). On the contrary, *S. albus* Del14 carrying the construct with deleted *alpE* gene was not able to produce alpiniamides (**Supplementary Figure [S13](#SM1){ref-type="supplementary-material"}**). Lastly, in order to determine the boundaries of *alp* gene cluster we performed the *blastn* search for the actinobacterial genome lacking the *alp* gene cluster but preserving the regions flanking the cluster in the genomes of *Streptomyces* sp. IB2014/011-12. As such, the *Kitasatospora albolonga* YIM 101047 and *Streptomyces* sp. IB2014/011-12 whole genome alignment have revealed that the *alp* gene cluster include gene between *alpA1* and *alpG*, when *alpR,D* and *alpW-I* are most probably not involved in alpiniamides biosynthesis (**Supplementary Figure [S14](#SM1){ref-type="supplementary-material"}**).

![LC-MS chromatogram RT 2--6 min out of an overall 9 min gradient run of extracts of *S. albus* Del14/011-12p1-49 and *S. lividans* TK24/011-12p1-49 strains carrying the *alp*-gene cluster construct. The strains were cultivated in NL19 media and compounds were extracted from the biomass. Peaks that correspond to alpiniamides are highlighted. Alpiniamide A-B (*m/z* 326 \[*M*-H~2~O+H\]^+^) and alpiniamide C (*m/z* 308 \[*M*-H~2~O+H\]^+^).](fmicb-09-01959-g005){#F5}

Deduction of Alpiniamide Biosynthesis
-------------------------------------

The predicted architecture of a hybrid NRPS-trans-AT-PKS mega-enzyme encoded by the *alp* gene cluster made it possible to propose the biosynthetic steps for the assembly of alpiniamides (**Figure [6B](#F6){ref-type="fig"}**). Polyketide synthases lacking the acyltransferase (trans-AT-PKS) were thought to be rare systems in actinomycetes. Only recently it has been discovered that they are present in several actinobacterial strains ([@B24]). However, in general, this type of PKS enzymes is thought to be the major class of polyketide biosynthesis machineries. In these systems the usual in-line acyltransferase domains are missing, and instead, free-standing enzymes take their place ([@B29]). Apparently, the orientation and location of the core genes in the *alp*-gene cluster do not reflect the order of the biosynthetic steps in alpiniamide assembly. The organization of the *alp* gene cluster lacks the co-linearity due to its unusual domain orders and domains acting across modules, which is a well-known feature of trans-AT-PKSs ([@B24]).

![Scheme of the organization of *alp*-gene cluster **(A)**. The line above shows the deduced boundaries of the cluster. The scale bar corresponds to 2 kb. Proposed pathway for the biosynthesis of alpiniamide **(B)**. Domains: KS - ketosynthase, AT, acyltransferase; DH, dehydratase; KR, ketoreductase; ACP, acyl carrier protein; cM, C-methyltransferase; AD, acyl-transferase docking domain; TE, thioesterase; C, condensation; A, adenylation; DHt, truncated dehydratase. ^∗^Indicates the DH presumably responsible for double bond migration and corresponding position at growing alpiniamide chain.](fmicb-09-01959-g006){#F6}

The synthesis is initiated by the loading module 0, which is part of the bimodular protein encoded by gene *alpA1* (12750) (**Table [2](#T2){ref-type="table"}**). Unlike the others, this module possesses its own AT domain that is predicted to be specific for methylmalonate. Since the starter unit in alpiniamide biosynthesis is thought to be a propionate, we believe that loading module 0 loads the methylmalonate and then decarboxylates it to produce propionate. Such a decarboxylative loading process is known for several *cis*-AT-PKS systems, including the ones involved in the biosynthesis of tylosin, niddamycin, pikromycin, spinosyn, and monensin ([@B15]; [@B68]). However, unlike the cis-AT systems, which typically harbor a KS^Q^ decarboxylative domain with the active site Cys mutated to a Gln, the Cys in the canonical CHH motif of AlpA1 KS0 is substituted with a Ser (KS^S^). Similar substitutions were found in the loading KS of trans-AT oocydin synthase ([@B43]) and several cis-AT PKSs from the nystatin, rimocidin, and pimaricin biosynthesis ([@B2]; [@B8]; [@B53]). These KS^S^ domains are proposed to participate in decarboxylation or synthesis of the starter substrates. At least in the case of the nystatin loading module, it was shown that the Ser residue of KS^S^0 is not crucial for proper initiation of the biosynthesis ([@B8]). However, in all of the cases described above, the polyketide chain is initiated by acetate rather than propionate. At the same time, another scenario cannot be excluded. The *alpE* gene located close to *alpA~1~* is predicted to encode the KSIII enzyme. This enzyme is similar to the daunorubicin loading KS as well as to the ACP-shuttle-type KSs from several other anthracycline polyketides that are initiated with a propionate starter unit, such as cosmomycin D and cinerubin B ([@B17]; [@B31]). The high similarity between AlpE and these KSs point on alternative scenario at which the decarboxylative function of the loading module in alpiniamides assembly might be provided by the standalone decarboxylative KSIII, similar to daunorubicin/aklavinone biosynthesis ([@B58]). The essentiality of AlpE for the production of alpiniamides in heterologous hosts supports this idea.

Subsequently, two elongation steps conducted by module 1 and 2 occur and incorporate two units of malonate. The substrate is passed on to the PKS by the trans-acting acyltransferase encoded by gene 12740. This protein is a bidomain AT-ACP enzyme that is predicted to be specific for malonate. The function of the ACP domain cannot be deduced from the available data, but it harbors a Ser residue for attachment of phosphopantetheine. Module 1 possesses KR and DH domains for ketoreduction and dehydration reactions, respectively. As expected, a double bond is present in alpiniamide A, C, and D between C-4 and C-5. However, in the case of alpiniamides B~1~ and B~2~, the DH domain is apparently skipped, resulting in a hydroxyl group at C-5. The ketoreductase domain is missing in module 2; although, alpiniamides have the hydroxyl group at the corresponding position. A possible explanation for this would be that the activity of the KR domain from module 1 is shared between modules 1 and 2. Interestingly B~1~ and B~2~ differ in the stereochemistry at C-5 position. Ketoreductases are highly stereospecific and are divided into groups depending on which stereochemistry they provide ([@B30]). The *in silico* analysis of module 1 KR place it in B1 stereospecificity type performing D-α-reduction that correspond to the configuration observed in alpiniamide B~2~ ([@B34]). Therefore, it is unclear how the different stereochemistry at position C-5 as well as the *threo* configuration at C-2/C-3 is generated. Module 2 has a C-methyltransferase domain. The acyltransferases in trans-AT-PKS are known to solely utilize malonyl-CoA as opposed to branched substrates as elongation units, and the side chain methyl groups are typically incorporated by C-methyltransferases. This seems to also be true in the case of the alpiniamides. From the labeled methionine feeding experiment, we clearly see that the methyl groups of the alpiniamides are introduced by the S-adenosyl-methionine (SAM) dependent methyltransferases present in module 2 and 4. Since these compounds each contain four methyl groups, we assume that both methyltransferases need to act twice during the biosynthesis. Thus, modules 2 and 4 provide the C-methyltransferase activity also to module 1 and 5. Another key feature of module 2 is the presence of a thioesterase domain. This TE is predicted to be a class II TE of the α/β hydrolase family. These enzymes hydrolyze the residues attached to the phosphopantetheine group of ACPs. The exact function of the TE domain of AlpA2 is not clear, especially considering its location. A similar architecture was observed in the case of the burkholderic acid trans-AT PKS, which harbors internal TE domains with unknown functions ([@B16]). TE II domains are often not essential for biosynthesis, but can be involved in removing aberrant substrates from stalled PKS megasynthases and control the loading of the starter unit ([@B36]). The TE domain of AlpA2 has the Cys in place of Ser residue of catalytic triad Ser/Asp/His (**Supplementary Figure [S15](#SM1){ref-type="supplementary-material"}**). However, such substitutions are not rare and can be found in TE14 family of thioesterases ([@B10]).

Another interesting feature of module 2 is the possible migration of the double bond. The double bond in alpiniamides B~1~ and B~2~ is shifted from the canonical position between C-2 and C-3 to the position between C-3 and C-4. A so-called double bond migration is described for several trans-AT produced polyketides such as bacillaene, corallopyronin A, and rhizoxin ([@B9]; [@B49]; [@B39]), and this process is thought to be mediated by a dehydratase domain either by direct β-γ dehydration or α-β dehydration and subsequent isomerization ([@B18]). However, it is not clear if alpiniamides B~1~ and B~2~ arise from alpiniamide A through the catalytic action of one of the DH domains (most likely by the DHt of module 5 that is predicted to be non-functional) or from an acid-induced double bond migration.

At the next step, a non-ribosomal peptide synthetase module within AlpA~3~ extend the polyketide intermediate with a glycine. Interestingly, glycine is often found to act as a bridge between two polyketide chains in hybrid NRPS-trans-AT-PKS assembled natural products, such as bacillaene, batumin, calyculin, corallopyronin, misakinolide and oxazolomycin ([@B24]).

Modules 4 and 5 further extend the molecule with two malonate units. Typically, ketosynthases ensuing a NRPS module are highly substrate specific and do rarely accept aberrant substrates with bulkier amino acid residues ([@B35]). As in module 2, module 4 lacks the ketoreductive function even though the hydroxy group at C-3′ is present. This activity is most likely provided by module 5, which contains KR and DH domains. However, based on the structures of alpiniamide A, B and D, we assume that the DH domain is occasionally skipped. Only alpiniamide C seems to be dehydrated at this step, which resulted in the double bond between C-3′ and C-4′. Module 5 is missing the ACP and TE domains, which are instead located in module 2. The mechanism by which alpiniamides are released from the biosynthetic enzyme is not clear. Most likely, the TE activity is provided by the respective domain of module 2. However, the location of the TE domain is unusual as well as the composition of catalytic triad (Cys/Asp/His). The fact that it is placed right before the NRPS module 3 makes us think that it also might be involved in the cleavage of aberrant substrates than in the release of the final product.

In the case of alpiniamide D, module 2 is probably skipped entirely during the biosynthesis since it lacks the C-1 and C-2 part of the molecule. Such a case is very rare but was previously described for epothilone K ([@B46]) and for the trans-AT-PKS-derived compound albicidin ([@B27]).

Even though alpiniamides are quite small molecules they provide a fascinating example of high chemical diversity introduced by the PKS assembly line. The alpiniamides NRPS-trans-AT-PKS utilizes a combination of domain and module skipping, in-line methylation and double bond migration events to produce a variety of chemical structures from a simple initial building block.

Conclusion
==========

We have isolated five new alpiniamide derivatives and identified the gene cluster responsible for their biosynthesis in the new *Streptomyces* sp. IB2014/011-12. This shows that there are still great opportunities to discover promising natural products, especially from unique and largely unexplored ecological niches such as Lake Baikal.
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